LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Reports of three long-term lung disease following SARS-CoV-2 infection.

    Piantoni, Silvia / Salada, Luisa / Colombo, Enrico / Mendeni, Monia / Damiolini, Ezio / Gatta, Diego / Richini, Donata / Furloni, Roberto / Airò, Paolo / Scarsi, Mirko

    Journal of medical virology

    2021  Volume 93, Issue 5, Page(s) 2585–2587

    MeSH term(s) Adult ; Aged, 80 and over ; COVID-19/complications ; COVID-19/pathology ; COVID-19/therapy ; Combined Modality Therapy ; Female ; Humans ; Lung/pathology ; Lung Diseases/etiology ; Lung Diseases/pathology ; Lung Diseases/therapy ; Male ; Middle Aged ; Recurrence ; SARS-CoV-2/pathogenicity ; Treatment Outcome
    Language English
    Publishing date 2021-02-09
    Publishing country United States
    Document type Case Reports ; Letter
    ZDB-ID 752392-0
    ISSN 1096-9071 ; 0146-6615
    ISSN (online) 1096-9071
    ISSN 0146-6615
    DOI 10.1002/jmv.26831
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1320: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome.

    Scarsi, Mirko / Piantoni, Silvia / Colombo, Enrico / Airó, Paolo / Richini, Donata / Miclini, Marco / Bertasi, Valeria / Bianchi, Marta / Bottone, Damiano / Civelli, Patrizia / Cotelli, Maria-Sofia / Damiolini, Ezio / Galbassini, Gloria / Gatta, Diego / Ghirardelli, Maria-Laura / Magri, Roberto / Malamani, Paola / Mendeni, Monia / Molinari, Stefano /
    Morotti, Andrea / Salada, Luisa / Turla, Marinella / Vender, Angiola / Tincani, Angela / Brucato, Antonio / Franceschini, Franco / Furloni, Roberto / Andreoli, Laura

    Annals of the rheumatic diseases

    2020  Volume 79, Issue 10, Page(s) 1286–1289

    Abstract: Objectives: The outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, ... ...

    Abstract Objectives: The outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, colchicine was proposed to patients with COVID-19, and its effects compared with 'standard-of-care' (SoC).
    Methods: In the public hospital of Esine, northern Italy, 140 consecutive inpatients, with virologically and radiographically confirmed COVID-19 admitted in the period 5-19 March 2020, were treated with 'SoC' (hydroxychloroquine and/or intravenous dexamethasone; and/or lopinavir/ritonavir). They were compared with 122 consecutive inpatients, admitted between 19 March and 5 April 2020, treated with colchicine (1 mg/day) and SoC (antiviral drugs were stopped before colchicine, due to potential interaction).
    Results: Patients treated with colchicine had a better survival rate as compared with SoC at 21 days of follow-up (84.2% (SE=3.3%)
    Conclusion: This proof-of-concept study may support the rationale of use of colchicine for the treatment of COVID-19. Efficacy and safety must be determined in controlled clinical trials.
    MeSH term(s) Aged ; Aged, 80 and over ; Anti-Inflammatory Agents/therapeutic use ; Antiviral Agents/therapeutic use ; Betacoronavirus ; COVID-19 ; Case-Control Studies ; Cohort Studies ; Colchicine/therapeutic use ; Coronavirus Infections/complications ; Coronavirus Infections/drug therapy ; Coronavirus Infections/mortality ; Dexamethasone/therapeutic use ; Drug Combinations ; Enzyme Inhibitors/therapeutic use ; Female ; Hospitalization ; Humans ; Hydroxychloroquine/therapeutic use ; Italy ; Lopinavir/therapeutic use ; Male ; Middle Aged ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/mortality ; Proof of Concept Study ; Proportional Hazards Models ; Respiratory Distress Syndrome/drug therapy ; Respiratory Distress Syndrome/etiology ; Respiratory Distress Syndrome/mortality ; Ritonavir/therapeutic use ; SARS-CoV-2 ; Survival Rate ; COVID-19 Drug Treatment
    Chemical Substances Anti-Inflammatory Agents ; Antiviral Agents ; Drug Combinations ; Enzyme Inhibitors ; lopinavir-ritonavir drug combination ; Lopinavir (2494G1JF75) ; Hydroxychloroquine (4QWG6N8QKH) ; Dexamethasone (7S5I7G3JQL) ; Ritonavir (O3J8G9O825) ; Colchicine (SML2Y3J35T)
    Keywords covid19
    Language English
    Publishing date 2020-07-30
    Publishing country England
    Document type Journal Article
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/annrheumdis-2020-217712
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.114: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 167: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide.

    Quiros-Roldan, Eugenia / Tirelli, Valeria / Torti, Carlo / Sosta, Elena / Tosoni, Cinzia / Damiolini, Ezio / Carosi, Giampiero

    AIDS (London, England)

    2007  Volume 21, Issue 10, Page(s) 1388–1389

    MeSH term(s) Adult ; Desensitization, Immunologic/methods ; Drug Hypersensitivity/therapy ; Female ; HIV Envelope Protein gp41/adverse effects ; HIV Fusion Inhibitors/adverse effects ; Humans ; Long-Term Care ; Peptide Fragments/adverse effects ; Treatment Outcome
    Chemical Substances HIV Envelope Protein gp41 ; HIV Fusion Inhibitors ; Peptide Fragments ; enfuvirtide (19OWO1T3ZE)
    Language English
    Publishing date 2007-06-19
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 639076-6
    ISSN 1473-5571 ; 0269-9370 ; 1350-2840
    ISSN (online) 1473-5571
    ISSN 0269-9370 ; 1350-2840
    DOI 10.1097/QAD.0b013e328136c54b
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2228: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome

    Scarsi, Mirko / Piantoni, Silvia / Colombo, Enrico / Airó, Paolo / Richini, Donata / Miclini, Marco / Bertasi, Valeria / Bianchi, Marta / Bottone, Damiano / Civelli, Patrizia / Cotelli, Maria-Sofia / Damiolini, Ezio / Galbassini, Gloria / Gatta, Diego / Ghirardelli, Maria-Laura / Magri, Roberto / Malamani, Paola / Mendeni, Monia / Molinari, Stefano /
    Morotti, Andrea / Salada, Luisa / Turla, Marinella / Vender, Angiola / Tincani, Angela / Brucato, Antonio / Franceschini, Franco / Furloni, Roberto / Andreoli, Laura

    Ann Rheum Dis

    Abstract: OBJECTIVES: The outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, ... ...

    Abstract OBJECTIVES: The outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, colchicine was proposed to patients with COVID-19, and its effects compared with 'standard-of-care' (SoC). METHODS: In the public hospital of Esine, northern Italy, 140 consecutive inpatients, with virologically and radiographically confirmed COVID-19 admitted in the period 5-19 March 2020, were treated with 'SoC' (hydroxychloroquine and/or intravenous dexamethasone; and/or lopinavir/ritonavir). They were compared with 122 consecutive inpatients, admitted between 19 March and 5 April 2020, treated with colchicine (1 mg/day) and SoC (antiviral drugs were stopped before colchicine, due to potential interaction). RESULTS: Patients treated with colchicine had a better survival rate as compared with SoC at 21 days of follow-up (84.2% (SE=3.3%) vs 63.6% (SE=4.1%), p=0.001). Cox proportional hazards regression survival analysis showed that a lower risk of death was independently associated with colchicine treatment (HR=0.151 (95% CI 0.062 to 0.368), p<0.0001), whereas older age, worse PaO2/FiO2, and higher serum levels of ferritin at entry were associated with a higher risk. CONCLUSION: This proof-of-concept study may support the rationale of use of colchicine for the treatment of COVID-19. Efficacy and safety must be determined in controlled clinical trials.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #689316
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Book ; Online: Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome

    Scarsi, Mirko / Piantoni, Silvia / Colombo, Enrico / Airó, Paolo / Richini, Donata / Miclini, Marco / Bertasi, Valeria / Bianchi, Marta / Bottone, Damiano / Civelli, Patrizia / Cotelli, Maria-Sofia / Damiolini, Ezio / Galbassini, Gloria / Gatta, Diego / Ghirardelli, Maria-Laura / Magri, Roberto / Malamani, Paola / Mendeni, Monia / Molinari, Stefano /
    Morotti, Andrea / Salada, Luisa / Turla, Marinella / Vender, Angiola / Tincani, Angela / Brucato, Antonio / Franceschini, Franco / Furloni, Roberto / Andreoli, Laura

    2020  

    Abstract: ... Objectives ... The outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the ... ...

    Abstract <sec><st>Objectives</st> The outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, colchicine was proposed to patients with COVID-19, and its effects compared with ‘standard-of-care’ (SoC). </sec> <sec><st>Methods</st> In the public hospital of Esine, northern Italy, 140 consecutive inpatients, with virologically and radiographically confirmed COVID-19 admitted in the period 5–19 March 2020, were treated with ‘SoC’ (hydroxychloroquine and/or intravenous dexamethasone; and/or lopinavir/ritonavir). They were compared with 122 consecutive inpatients, admitted between 19 March and 5 April 2020, treated with colchicine (1 mg/day) and SoC (antiviral drugs were stopped before colchicine, due to potential interaction). </sec> <sec><st>Results</st> Patients treated with colchicine had a better survival rate as compared with SoC at 21 days of follow-up (84.2% (SE=3.3%) vs 63.6% (SE=4.1%), p=0.001). Cox proportional hazards regression survival analysis showed that a lower risk of death was independently associated with colchicine treatment (HR=0.151 (95% CI 0.062 to 0.368), p<0.0001), whereas older age, worse PaO2/FiO2, and higher serum levels of ferritin at entry were associated with a higher risk. </sec> <sec><st>Conclusion</st> This proof-of-concept study may support the rationale of use of colchicine for the treatment of COVID-19. Efficacy and safety must be determined in controlled clinical trials. </sec>
    Keywords Epidemiology ; covid19
    Language English
    Publishing date 2020-10-01 00:00:00.0
    Publisher BMJ Publishing Group Ltd
    Publishing country us
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome

    Scarsi, Mirko / Piantoni, Silvia / Colombo, Enrico / Airo', Paolo / Richini, Donata / Miclini, Marco / Bertasi, Valeria / Bianchi, Marta / Bottone, Damiano / Civelli, Patrizia / Cotelli, Maria Sofia / Damiolini, Ezio / Galbassini, Gloria / Gatta, Diego / Ghirardelli, Maria-Laura / Magri, Roberto / Malamani, Paola / Mendeni, Monia / Molinari, Stefano /
    Morotti, Andrea / Salada, Luisa / Turla, Marinella / Vender, Angiola / Tincani, Angela / Brucato, Antonio / Franceschini, Franco / Furloni, Roberto / Andreoli, Laura

    2020  

    Abstract: Objectives: The outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, ... ...

    Abstract Objectives: The outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, colchicine was proposed to patients with COVID-19, and its effects compared with 'standard-of-care' (SoC). Methods: In the public hospital of Esine, northern Italy, 140 consecutive inpatients, with virologically and radiographically confirmed COVID-19 admitted in the period 5-19 March 2020, were treated with 'SoC' (hydroxychloroquine and/or intravenous dexamethasone; and/or lopinavir/ritonavir). They were compared with 122 consecutive inpatients, admitted between 19 March and 5 April 2020, treated with colchicine (1 mg/day) and SoC (antiviral drugs were stopped before colchicine, due to potential interaction). Results: Patients treated with colchicine had a better survival rate as compared with SoC at 21 days of follow-up (84.2% (SE=3.3%) vs 63.6% (SE=4.1%), p=0.001). Cox proportional hazards regression survival analysis showed that a lower risk of death was independently associated with colchicine treatment (HR=0.151 (95% CI 0.062 to 0.368), p<0.0001), whereas older age, worse PaO2/FiO2, and higher serum levels of ferritin at entry were associated with a higher risk. Conclusion: This proof-of-concept study may support the rationale of use of colchicine for the treatment of COVID-19. Efficacy and safety must be determined in controlled clinical trials
    Keywords anti-inflammatory agents ; non-steroidal ; antirheumatic agents ; communicable diseases ; imported ; inflammation ; therapeutics ; covid19
    Subject code 616
    Language English
    Publishing country it
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article ; Online: Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome

    Scarsi, Mirko / Piantoni, Silvia / Colombo, Enrico / Airó, Paolo / Richini, Donata / Miclini, Marco / Bertasi, Valeria / Bianchi, Marta / Bottone, Damiano / Civelli, Patrizia / Cotelli, Maria-Sofia / Damiolini, Ezio / Galbassini, Gloria / Gatta, Diego / Ghirardelli, Maria-Laura / Magri, Roberto / Malamani, Paola / Mendeni, Monia / Molinari, Stefano /
    Morotti, Andrea / Salada, Luisa / Turla, Marinella / Vender, Angiola / Tincani, Angela / Brucato, Antonio / Franceschini, Franco / Furloni, Roberto / Andreoli, Laura

    Annals of the Rheumatic Diseases

    2020  Volume 79, Issue 10, Page(s) 1286–1289

    Abstract: Objectives The outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, ... ...

    Abstract Objectives The outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, colchicine was proposed to patients with COVID-19, and its effects compared with ‘standard-of-care’ (SoC). Methods In the public hospital of Esine, northern Italy, 140 consecutive inpatients, with virologically and radiographically confirmed COVID-19 admitted in the period 5–19 March 2020, were treated with ‘SoC’ (hydroxychloroquine and/or intravenous dexamethasone; and/or lopinavir/ritonavir). They were compared with 122 consecutive inpatients, admitted between 19 March and 5 April 2020, treated with colchicine (1 mg/day) and SoC (antiviral drugs were stopped before colchicine, due to potential interaction). Results Patients treated with colchicine had a better survival rate as compared with SoC at 21 days of follow-up (84.2% (SE=3.3%) vs 63.6% (SE=4.1%), p=0.001). Cox proportional hazards regression survival analysis showed that a lower risk of death was independently associated with colchicine treatment (HR=0.151 (95% CI 0.062 to 0.368), p<0.0001), whereas older age, worse PaO2/FiO2, and higher serum levels of ferritin at entry were associated with a higher risk. Conclusion This proof-of-concept study may support the rationale of use of colchicine for the treatment of COVID-19. Efficacy and safety must be determined in controlled clinical trials.
    Keywords Immunology ; General Biochemistry, Genetics and Molecular Biology ; Immunology and Allergy ; Rheumatology ; covid19
    Language English
    Publisher BMJ
    Publishing country uk
    Document type Article ; Online
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/annrheumdis-2020-217712
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.114: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 167: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top